PATIENT Engagement Program (PEP) growth has resulted in 18 medications bringing education programs, up from eight medications only 12 months ago, digital medical adherence company MedAdvisor has announced.
The PEPs now reach some 55,000 patients, the company said in an ASX statement, with nine of Australia's largest pharmaceutical companies engaged including Novartis, Bristol-Myers Squibb, GSK, AstraZeneca and now Pfizer (PD 09 Dec 16).
PEPs generate an ongoing income stream the company said adding that the integration of the recently acquired Healthnotes (PD 20 Oct, 01 Nov 16) is progressing well with Healthnotes staff now contributing their "considerable skills and depth of knowledge to the team".
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Dec 16
